1. Dibyajyoti S, Bin ET, Swati P. Bioinformatics: The effects on the cost of drug discovery. Galle Medical Journal. 2013;18(1). [DOI:10.4038/gmj.v18i1.5511]

2. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. Journal of health economics. 2003;22(2):151-85. [DOI:10.1016/S0167-6296(02)00126-1] [PMID]

3. Raslan MA, Raslan SA, Shehata EM, Mahmoud AS, Sabri NA. Advances in the Applications of Bioinformatics and Chemoinformatics. Pharmaceuticals (Basel, Switzerland). 2023;16(7). [DOI:10.3390/ph16071050] [PMID] []

4. Brown D, Superti-Furga G. Rediscovering the sweet spot in drug discovery. Drug discovery today. 2003;8(23):1067-77. [DOI:10.1016/S1359-6446(03)02902-7] [PMID]

5. Xia X. Bioinformatics and Drug Discovery. Current topics in medicinal chemistry. 2017;17(15):1709-26. [DOI:10.2174/1568026617666161116143440] [PMID] []

6. Iskar M, Zeller G, Zhao X-M, van Noort V, Bork P. Drug discovery in the age of systems biology: the rise of computational approaches for data integration. Current opinion in biotechnology. 2012;23(4):609-16. [DOI:10.1016/j.copbio.2011.11.010] [PMID]

7. Whittaker PA. What is the relevance of bioinformatics to pharmacology? Trends in Pharmacological Sciences. 2003;24(8):434-9. [DOI:10.1016/S0165-6147(03)00197-4] [PMID]

8. Ortega SS, Cara LCL, Salvador MK. In silico pharmacology for a multidisciplinary drug discovery process. Drug metabolism and drug interactions. 2012;27(4):199-207. [DOI:10.1515/dmdi-2012-0021] [PMID]

9. Song CM, Lim SJ, Tong JC. Recent advances in computer-aided drug design. Briefings in bioinformatics. 2009;10(5):579-91. [DOI:10.1093/bib/bbp023] [PMID]

10. Speck-Planche A, Cordeiro M. Computer-aided drug design, synthesis and evaluation of new anti-cancer drugs. Curr Top Med Chem [Epub ahead of print]. 2013. [DOI:10.2174/15680266112129990082]

11. Macalino SJY, Gosu V, Hong S, Choi S. Role of computer-aided drug design in modern drug discovery. Archives of pharmacal research. 2015;38(9):1686-701. [DOI:10.1007/s12272-015-0640-5] [PMID]

12. Deore A, Dhumane J, Wagh R, Sonawane R. The Stages of Drug Discovery and Development Process. Asian Journal of Pharmaceutical Research and Development. 2019;7:62-7. [DOI:10.22270/ajprd.v7i6.616]

13. Yamanishi Y, Kotera M, Kanehisa M, Goto S. Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework. Bioinformatics. 2010;26(12):i246-i54. [DOI:10.1093/bioinformatics/btq176] [PMID] []

14. Gilbert J, Henske P, Singh A. Rebuilding big pharma's business model. IN VIVO-NEW YORK THEN NORWALK-. 2003;21(10):73-80.

15. Ratti E, Trist D. Continuing evolution of the drug discovery process in the pharmaceutical industry. Pure and Applied Chemistry. 2001;73(1):67-75. [DOI:10.1351/pac200173010067]

16. Adams CP, Brantner VV. Spending on new drug development. Health economics. 2010;19(2):130-41. [DOI:10.1002/hec.1454] [PMID]

17. Dickson M, Gagnon JP. Key factors in the rising cost of new drug discovery and development. Nature Reviews Drug Discovery. 2004;3(5):417-29. [DOI:10.1038/nrd1382] [PMID]

18. Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it? Acta pharmaceutica Sinica B. 2022;12(7):3049-62. [DOI:10.1016/j.apsb.2022.02.002] [PMID] []

19. Tsaioun K, Bottlaender M, Mabondzo A, Foundation AsDD, editors. ADDME-Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective. BMC neurology; 2009: Springer. [DOI:10.1186/1471-2377-9-S1-S1] [PMID] []

20. Klein D, Tabarrok A. The drug discovery, development and approval process. 2003.

21. Tamimi NA, Ellis P. Drug development: from concept to marketing! Nephron Clinical Practice. 2009;113(3):c125-c31. [DOI:10.1159/000232592] [PMID]

22. Wierenga DE, Eaton RC. Drug Development and Approval Process. Alliance Pharmaceutical Company. 2004.

23. Katara P. Role of bioinformatics and pharmacogenomics in drug discovery and development process. Network Modeling Analysis in Health Informatics and Bioinformatics. 2013;2(4):225-30. [DOI:10.1007/s13721-013-0039-5]

24. Dao N, Vu T-D. Bioinformatics in Drug Discovery. 2024. p. 239-48. [DOI:10.1007/978-981-99-8401-5_11]

25. Collier R. Rapidly rising clinical trial costs worry researchers. Can Med Assoc; 2009. [DOI:10.1503/cmaj.082041] [PMID] []

26. Myers S, Baker A. Drug discovery--an operating model for a new era. Nature biotechnology. 2001;19(8):727-31. [DOI:10.1038/90765] [PMID]

27. Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet journal of rare diseases. 2011;6(1):42. [DOI:10.1186/1750-1172-6-42] [PMID] []

28. Liang BA, Mackey T. Direct-to-consumer advertising with interactive internet media: global regulation and public health issues. Jama. 2011;305(8):824-5. [DOI:10.1001/jama.2011.203] [PMID]

29. Lindpaintner K. The impact of pharmacogenetics and pharmacogenomics on drug discovery. Nature Reviews Drug Discovery. 2002;1(6):463-9. [DOI:10.1038/nrd823] [PMID]

30. Shin J. Clinical pharmacogenomics of warfarin and clopidogrel. Journal of pharmacy practice. 2012;25(4):428-38. [DOI:10.1177/0897190012448310] [PMID]

31. Papanikolaw J. Bioinformatics emerges as key technology for developing new drugs. Chemical Market Reporter; May 24, 1999; 255, 21; ABI/INFORM Global pg. 1999;22.

32. Zemlo T. Pharmacogenomic promise, pitfalls. Drug Discovery & Development Highland Ranch. 2004;7(5).

33. de Lara DV, de Melo DO, Kawakami DY, Gonçalves TS, Santos PC. Pharmacogenetic testing-guided treatment for oncology: an overview of reviews. Pharmacogenomics. 2022;23(13):739-48. [DOI:10.2217/pgs-2022-0064] [PMID]

34. Amstutz U, Carleton B. Pharmacogenetic testing: time for clinical practice guidelines. Clinical Pharmacology & Therapeutics. 2011;89(6):924-7. [DOI:10.1038/clpt.2011.18] [PMID]

35. Liou S-Y, Stringer F, Hirayama M. The impact of pharmacogenomics research on drug development. Drug metabolism and pharmacokinetics. 2012;27(1):2-8. [DOI:10.2133/dmpk.DMPK-11-RV-093] [PMID]

36. Moe JL. Commercialization Considerations for Individualized Diagnostic and Drug Therapies Resulting from Pharmacogenomics. La L Rev. 2005;66:103.

37. Mounzer K, Hsu R, Fusco JS, Brunet L, Henegar CE, Vannappagari V, et al. HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study. AIDS Research and Therapy. 2019;16(1):1. [DOI:10.1186/s12981-019-0217-3] [PMID] []

38. Leeder JS, Gaedigk A, Wright KJ, Staggs VS, Soden SE, Lin YS, et al. A longitudinal study of cytochrome P450 2D6 (CYP2D6) activity during adolescence. 2022;15(10):2514-27. [DOI:10.1111/cts.13380] [PMID] []

39. Sun X, Yu WY, Ma WL, Huang LH, Yang GP. Impact of the CYP4F2 gene polymorphisms on the warfarin maintenance dose: A systematic review and meta-analysis. Biomedical reports. 2016;4(4):498-506. [DOI:10.3892/br.2016.599] [PMID] []

40. Takano M, Sugiyama T. UGT1A1 polymorphisms in cancer: impact on irinotecan treatment. Pharmacogenomics and personalized medicine. 2017;10:61-8. [DOI:10.2147/PGPM.S108656] [PMID] []

41. Kwok WC, Lam DCL, Ip MSM, Tam TCC, Ho JCM. Association of genetic polymorphisms of CYP3A4 and CYP2D6 with gefitinib-induced toxicities. Anti-cancer drugs. 2022;33(10):1139-44. [DOI:10.1097/CAD.0000000000001360] [PMID]

42. Dean L, Kane M. Codeine Therapy and CYP2D6 Genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries. Bethesda (MD): National Center for Biotechnology Information (US); 2012.

43. Yang H, Yang L, Zhong X, Jiang X, Zheng L, Wang L. Physiologically based pharmacokinetic modeling of brivaracetam and its interactions with rifampin based on CYP2C19 phenotypes. European Journal of Pharmaceutical Sciences. 2022;177:106258. [DOI:10.1016/j.ejps.2022.106258] [PMID]

44. Wigle TJ, Tsvetkova EV, Welch SA, Kim RB. DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report. Pharmaceutics. 2019;11(5). [DOI:10.3390/pharmaceutics11050199] [PMID] []

45. Prows CA, Prows DR. Medication Selection by Genotype: How genetics is changing drug prescribing and efficacy. AJN The American Journal of Nursing. 2004;104(5):60-70. [DOI:10.1097/00000446-200405000-00024] [PMID]

46. Rawlins MD. Cutting the cost of drug development? Nature reviews Drug discovery. 2004;3(4):360-4. [DOI:10.1038/nrd1347] [PMID]

47. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. Jama. 1998;279(15):1200-5. [DOI:10.1001/jama.279.15.1200] [PMID]

48. Becquemont L. Pharmacogenomics of adverse drug reactions: practical applications and perspectives. Pharmacogenomics. 2009;10(6):961-9. [DOI:10.2217/pgs.09.37] [PMID]

49. Hodkinson A, Tyler N, Ashcroft DM, Keers RN, Khan K, Phipps D, et al. Preventable medication harm across health care settings: a systematic review and meta-analysis. BMC Medicine. 2020;18(1):313. [DOI:10.1186/s12916-020-01774-9] [PMID] []

50. Auwerx C, Sadler MC, Reymond A, Kutalik Z. From pharmacogenetics to pharmaco-omics: Milestones and future directions. Human Genetics and Genomics Advances. 2022;3(2):100100. [DOI:10.1016/j.xhgg.2022.100100] [PMID] []

51. Nelson M, Bacanu S, Mosteller M, Li L, Bowman C, Roses A, et al. Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. The pharmacogenomics journal. 2009;9(1):23-33. [DOI:10.1038/tpj.2008.4] [PMID]

52. Erdmann A, Rehmann-Sutter C, Bozzaro C. Patients' and professionals' views related to ethical issues in precision medicine: a mixed research synthesis. BMC Medical Ethics. 2021;22(1):116. [DOI:10.1186/s12910-021-00682-8] [PMID] []

53. Thorn CF, Klein TE, Altman RB. Pharmacogenomics and bioinformatics: PharmGKB. Pharmacogenomics. 2010;11(4):501-5. [DOI:10.2217/pgs.10.15] [PMID] []

54. Bennett SJP. Solexa ltd. 2004;5(4):433-8. [DOI:10.1517/14622416.5.4.433] [PMID]

55. Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: translating science into practice. Clinical Pharmacology & Therapeutics. 2012;92(4):467-75. [DOI:10.1038/clpt.2012.120] [PMID] []

56. Gurgula O. Strategic Patenting by Pharmaceutical Companies - Should Competition Law Intervene? IIC; international review of industrial property and copyright law. 2020;51(9):1062-85. [DOI:10.1007/s40319-020-00985-0] [PMID] []

57. Maher PD, Haffner M. Orphan Drug Designation and Pharmacogenomics. BioDrugs. 2006;20(2):71-9. [DOI:10.2165/00063030-200620020-00001] [PMID]

58. Rioux PP. Clinical trials in pharmacogenetics and pharmacogenomics: methods and applications. American Journal of Health System Pharmacy. 2000;57(9):887-98. [DOI:10.1093/ajhp/57.9.887] [PMID]

59. Fermini B, Fossa AA. The impact of drug-induced QT interval prolongation on drug discovery and development. Nature reviews Drug discovery. 2003;2(6):439-47. [DOI:10.1038/nrd1108] [PMID]

60. Vanakker OM, De Paepe A. Pharmacogenomics in children: advantages and challenges of next generation sequencing applications. International journal of pediatrics. 2013;2013. [DOI:10.1155/2013/136524] [PMID] []

61. Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Translational research. 2009;154(6):277-87. [DOI:10.1016/j.trsl.2009.09.005] [PMID]

62. Haga SB, Burke W. Practical ethics: establishing a pathway to benefit for complex pharmacogenomic tests. Clinical Pharmacology